GleamWall
中文EN

CYTK CYTOKINETICS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1061983 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY29.9%
TTM net income YoY-3.5%
TTM EPS YoY4.4%
Revenue 3-yr CAGR143.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-625.2%
Net margin-686.6%
FCF margin-519.5%
EBITDA margin-613.2%

Returns

ROE—
ROA-47.7%
ROIC (approx.)—
Asset turnover0.07x

Leverage & solvency

Liabilities / assets117.6%
Debt / equity—
Current ratio3.36x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue14.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$88.04M$18.47M
R&D expense$416.03M$339.41M
SG&A expense$284.27M$215.31M
Operating income-$612.26M-$536.25M
Interest expense$45.58M$37.70M
Income tax$0$0
Net income-$784.96M-$589.53M
EBITDA-$602.13M-$526.72M
EPS (basic)-6.54-5.26
EPS (diluted)-6.54-5.26
Weighted avg. shares (diluted)120,103111,979
Balance sheet
Cash & equivalents$122.52M$94.86M
Short-term investments$759.70M$981.16M
Receivables$17.76M$16.65M
Inventory$0—
Current assets$916.98M$1.11B
PP&E, net$79.19M$65.81M
Total assets$1.42B$1.40B
Current liabilities$202.45M$179.67M
Short-term debt$41.18M$11.52M
Long-term debt$246.38M$93.23M
Total debt$287.56M$104.75M
Total liabilities$2.08B$1.54B
Shareholders' equity-$659.62M-$135.37M
Net debt$165.05M$9.89M
Shares outstanding122.94M118.21M
Cash flow statement
Operating cash flow-$510.01M-$395.89M
Capital expenditure$24.81M$3.91M
Free cash flow-$534.82M-$399.80M
Investing cash flow$16.67M-$553.10M
Financing cash flow$524.46M$930.61M
Depreciation & amortization$10.12M$9.53M
Stock-based compensation$112.29M$97.84M

Free plan shows the latest 2 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.